GSK4532990 is being developed under the November 2021 exclusive license agreement between Arrowhead and GSK. GSK received an exclusive license to develop and commercialize GSK4532990 in all territories except Greater China, which was retained by Arrowhead. GSK is wholly responsible for further clinical development and commercialization, outside of Greater China.

GSK4532990 targets HSD17B13, a member of the hydroxysteroid dehydrogenase family involved in the metabolism of hormones, fatty acids, and bile acids. Published human genetic data indicate that a loss of function mutation in HSD17B13 provides strong protection against alcoholic hepatitis, cirrhosis, and NASH, with approximately 30-50% risk reduction compared to non-carriers.¹

The double-blind, placebo-controlled Phase 2b HORIZON trial (NCT05583344) will evaluate the efficacy and safety of GSK4532990 in adults with pre-cirrhotic NASH. It will enroll up to 246 participants.